Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Cattle Diseases D002418 24 associated lipids
Fatty Liver D005234 48 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Kallmann R et al. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects. 1987 Thromb. Res. pmid:3576521
Filep J and Rosenkranz B Mechanism of vasopressin-induced platelet aggregation. 1987 Thromb. Res. pmid:3105115
Ushiyama S et al. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. 1988 Thromb. Res. pmid:3175990
Svensson J and Samuelsson K Inhibition of platelet function by low dose acetylsalicylic acid in patients with cerebrovascular disease. 1983 Thromb. Res. pmid:20218005
Rogasi PG et al. Radioimmunoassay of thromboxane B2 in plasma: methodological modifications. 1988 Thromb. Res. pmid:3175991
Takasaki W et al. Superiority of plasma 11-dehydro-TXB2 to TXB2 as an index of in vivo TX formation in rabbits after dosing of CS-518, a TX synthase inhibitor. 1993 Thromb. Res. pmid:8367836
Kosaki G et al. The mechanism of the inhibitory effect of protease inhibitors on platelet aggregation and cellular synthesis of prostaglandins. I. The effect on the release of arachidonic acid from phospholipids. 1980 Dec 1-15 Thromb. Res. pmid:6785893
Butler KD et al. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. 1987 Thromb. Res. pmid:3109067
Anfossi G et al. Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. 1995 Thromb. Res. pmid:7778055
Watanabe T et al. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. 2001 Thromb. Res. pmid:11672751
Lee GY et al. Antiplatelet activity of BRX-018, (6aS,cis)-malonic acid 3-acetoxy-6a9-bis-(2-methoxycarbonyl-acetoxy)-6,6a,7,11b-tetrahydro-indeno[2,1-c]chromen-10-yl ester methylester. 2005 Thromb. Res. pmid:15668191
Ljungberg B et al. Immediate effects of heparin and LMW heparin on some platelet and endothelial derived factors. 1988 Thromb. Res. pmid:2847353
Boyd JA and Eling TE Prostaglandin release and the interaction of platelets with the pulmonary vasculature of rat and guinea pig. 1980 Jul 1-15 Thromb. Res. pmid:7003800
Pedersen AK et al. Inhibition of thromboxane biosynthesis in serum: limitations of the measurement of immunoreactive 6-keto-PGF1 alpha. 1984 Thromb. Res. pmid:6546456
Addonizio VP et al. Inhibition of human platelet function by verapamil. 1982 Thromb. Res. pmid:7164035
Pekonen F et al. Platelet function and coagulation in normal and preeclamptic pregnancy. 1986 Thromb. Res. pmid:2944245
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Grauso F et al. Effects of iloprost (ZK 36374), a prostacyclin derivative, on platelet function after ischaemic exercise in patients with stable angina pectoris. 1987 Thromb. Res. pmid:2447664
Saldeen P et al. Thromboxane production in umbilical vein grafts. 1984 Thromb. Res. pmid:6546814
Chou TC and Li CY Inhibitory mechanisms of dantrolene on platelet aggregation. 1999 Thromb. Res. pmid:10593433
Davì G et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. 1982 Thromb. Res. pmid:6761893
Rousson D et al. Acute myocardial infarction: measurement of arachidonate end-products in whole blood as an index of platelet cyclo-oxygenase activity in vivo. 1987 Thromb. Res. pmid:3122356
Navran SS et al. Human platelet activation by bacterial phospholipase C is mediated by phosphatidylinositol hydrolysis but not generation of phosphatidic acid: inhibition by a selective inhibitor of phospholipase C. 1984 Thromb. Res. pmid:6372157
Vanags D et al. The antiplatelet effect of daily low dose enteric-coated aspirin in man: a time course of onset and recovery. 1990 Thromb. Res. pmid:2264023
Cerskus AL et al. Thromboxane B2 and 6-keto-prostaglandin F1 alpha synthesis during infusion of collagen and arachidonic acid in rabbits: inhibition by aspirin and sulfinpyrazone. 1980 Thromb. Res. pmid:7414555
Castaldi PA et al. Evidence for a platelet membrane defect in the myeloproliferative syndromes. 1982 Thromb. Res. pmid:6960545
Kankuri E et al. Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. 2003 Thromb. Res. pmid:14592552
Davis RB et al. Evaluation of platelet function in pregnancy. Comparative studies in non-smokers and smokers. 1987 Thromb. Res. pmid:2955542
Di Minno G et al. Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides. 1982 Thromb. Res. pmid:6803385
Catella F and FitzGerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. 1987 Thromb. Res. pmid:3686481
Suehiro A et al. The role of platelet hyperfunction in thrombus formation in hyperlipidemia. 1982 Thromb. Res. pmid:6803387
Vericel E et al. Platelets and aging. I--Aggregation, arachidonate metabolism and antioxidant status. 1988 Thromb. Res. pmid:3129819
Arruzazabala ML et al. Effects of Policosanol on platelet aggregation in rats. 1993 Thromb. Res. pmid:8475481
Reis F et al. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. 1999 Thromb. Res. pmid:10605951
Riess H et al. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. 1984 Thromb. Res. pmid:6237460
Cattaneo M et al. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. 1991 Thromb. Res. pmid:1926062
Weide I et al. Effects of cyclooxygenase inhibitors on ex vivo cysteinyl-leukotriene production by whole human blood allowed to clot spontaneously. Comparison to stimulated blood. 1992 Thromb. Res. pmid:1440511
Udvardy M et al. Alterations of primary haemostasis in mixed connective tissue disease (MCTD). 1991 Thromb. Res. pmid:1835548
Patrono C et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. 1980 Feb 1-15 Thromb. Res. pmid:7368167
Koh H et al. A radioimmunoassay of thromboxane B2 with thromboxane B2-125I-tyramide and its application to the study on the thromboxane B2 formation during platelet aggregation. 1980 Feb 1-15 Thromb. Res. pmid:7368170
Tindall H et al. Thrombin generation precedes platelet activation in native blood taken from the hand during multiple blood sampling following cold challenge. 1987 Thromb. Res. pmid:3617016
Kohda N et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. 1999 Thromb. Res. pmid:10593428
Deckmyn H et al. Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure. 1983 Thromb. Res. pmid:6344317
Winther K et al. Platelet function and fibrinolytic activity in cervical spinal cord injured patients. 1992 Thromb. Res. pmid:1321515
Chetty N and Bradlow BA The effects of a vegetarian diet on platelet function and fatty acids. 1983 Thromb. Res. pmid:6612688
Vesterqvist O et al. Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans. 1984 Thromb. Res. pmid:6695361
Lee TK et al. Comparison of the effect of acetylsalicylic acid on platelet function in male and female patients with ischemic stroke. 1987 Thromb. Res. pmid:3629557
Tanoue K et al. A new variant of thrombasthenia with abnormally glycosylated GP IIb/IIIa. 1987 Thromb. Res. pmid:3629560
Altman R and Scazziota A Synergistic actions of paf-acether and sodium arachidonate in human platelet aggregation. 2. Unexpected results after aspirin intake. 1986 Thromb. Res. pmid:3088757
Franconi F et al. Effect of gamma-hydroxybutyric acid on human platelet aggregation in vitro. 2001 Thromb. Res. pmid:11369419
Petroni A et al. Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. 1995 Thromb. Res. pmid:7482432
De La Cruz JP et al. Antithrombotic potential of olive oil administration in rabbits with elevated cholesterol. 2000 Thromb. Res. pmid:11113274
Barnhart MI et al. DDAVP: does the drug have a direct effect on the vessel wall? 1983 Thromb. Res. pmid:6415852
Todd MK et al. Effect of exercise intensity on 6-keto-PGF1 alpha, TXB2, and 6-keto-PGF1 alpha/TXB2 ratios. 1992 Thromb. Res. pmid:1615492
Davì G et al. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs. 1985 Thromb. Res. pmid:2933846
Dembinska-Kiec A et al. Ticlopidine and platelet function in healthy volunteers. 1992 Thromb. Res. pmid:1615496
Saldeen P and Saldeen T 6-keto-prostaglandin F1 alpha/thromboxane B2 ratio in vascular and lung tissue. 1983 Thromb. Res. pmid:6688484
Sandler H et al. Studies on the role of thromboxane in thrombin-induced pulmonary insufficiency in the rat. 1986 Thromb. Res. pmid:3754987
Pattison A et al. The in vitro effect of amrinone on thromboxane B2 synthesis in human whole blood. 1986 Thromb. Res. pmid:3755259
Maguire ED and Wallis RB In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. 1983 Thromb. Res. pmid:6689221
Di Minno MN et al. Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis. 2011 Thromb. Res. pmid:21669453
Lagarde M et al. Increase of platelet thromboxane A2 formation and of its plasmatic half-life in diabetes mellitus. 1980 Thromb. Res. pmid:7466751
Ames PR et al. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. 2012 Thromb. Res. pmid:22521214
McGill D et al. Platelet function and exercise-induced myocardial ischaemia in coronary heart disease patients. 1989 Thromb. Res. pmid:2533414
Li C et al. Aspirin response variability after major orthopedic surgery. 2012 Thromb. Res. pmid:22575418
Weide I et al. Intravascular cysteinyl-leukotriene formation by clotting whole human blood. Evidence from clamped umbilical vein segments and thrombus specimens. 1993 Thromb. Res. pmid:8122190
Uyama O et al. Plasma concentrations of 6-keto-prostaglandin F1 alpha in patients with hypertension, cerebrovascular disease or Takayasu's arteritis. 1982 Jan 1-15 Thromb. Res. pmid:6121391
Voss R et al. In vitro and ex vivo effects of aspirin in patients on a low-dose aspirin therapy. 1993 Thromb. Res. pmid:8122187
Croft KD and Beilin LJ Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. 1993 Thromb. Res. pmid:8385810
Takasaki W et al. Enzyme immunoassay of human plasma 11-dehydrothromboxane B2. 1991 Thromb. Res. pmid:1957275
Hofmann D et al. Evidence for sustained platelet activation in patients with early postinfarction angina. 1993 Thromb. Res. pmid:8303651
Toft G et al. Intravenously and topically applied magnesium in the prevention of arterial thrombosis. 2000 Thromb. Res. pmid:10904104
Korth R et al. Unsaturated platelet-activating factor: influence on aggregation, serotonin release and thromboxane synthesis of human thrombocytes. 1986 Thromb. Res. pmid:3961742
Schmid P et al. Passive smoking and platelet thromboxane. 1996 Thromb. Res. pmid:8907294
Sinzinger H et al. Response of thromboxane B2, malondialdehyde and platelet sensitivity to 3 weeks low-dose aspirin (ASA) in healthy volunteers. 1989 Thromb. Res. pmid:2497545
Riess H et al. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients. 1986 Thromb. Res. pmid:3012819
Pirich C et al. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. 1999 Thromb. Res. pmid:10588465
Altman R et al. Synergistic actions of PAF-acether and sodium arachidonate in human platelet aggregation. 1. Studies in normal human platelet rich plasma. 1986 Thromb. Res. pmid:3014677
Teng CM et al. Platelet aggregation induced by equinatoxin. 1988 Thromb. Res. pmid:2906181
Selley ML et al. The effect of cholesterol oxidation products on human platelet aggregation. 1996 Thromb. Res. pmid:8885139
De Caterina R et al. Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. 1990 Thromb. Res. pmid:2126400
Yamaguchi A et al. Effect of cetiedil on platelet aggregation and thromboxane synthesis. 1985 Thromb. Res. pmid:2986312
Lai LJ et al. Trilinolein inhibits epinephrine-induced human platelet aggregation. 1994 Thromb. Res. pmid:7863478
Wu TM et al. Inhibitory effect of hexapeptide (RGRHGD) on platelet aggregation. 2000 Thromb. Res. pmid:10674405
Ding YA et al. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. 1995 Thromb. Res. pmid:7740521
Leoncini G et al. In retinal vein occlusion platelet response to thrombin is increased. 2009 Thromb. Res. pmid:19660790
Perneby C et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. 1999 Thromb. Res. pmid:10632465
Prosdocimi M et al. Inhibition by AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonyl methoxy coumarin) of platelet aggregation in dog stenosed coronary artery. 1985 Thromb. Res. pmid:3840290
Schorer AE and White JG Interleukin 1 enhances arterial thrombogenicity in vitro. 1989 Thromb. Res. pmid:2609290
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Udvardy M et al. Altered primary haemostasis in Conn's syndrome. 1992 Thromb. Res. pmid:1448795
Simmet T and Weide I Thromboxane and cysteinyl-leukotriene formation are differentially activated in spontaneously clotting whole human blood in vitro. 1991 Thromb. Res. pmid:1866709
De la Cruz JP et al. Effect of erythrocytes and prostacyclin production in the effect of fructose and sorbitol on platelet activation in human whole blood in vitro. 1997 Thromb. Res. pmid:9219331
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Delvos U et al. Direct radioimmunological measurement of thromboxane B2 in plasma. 1985 Thromb. Res. pmid:4082109
Swart SS et al. Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders. 1984 Thromb. Res. pmid:6326344
Ito T et al. Role of activated platelets in endotoxin-induced DIC in rats. 1990 Thromb. Res. pmid:2080492
Alessandrini P et al. Physiologic variables affecting thromboxane B2 production in human whole blood. 1985 Thromb. Res. pmid:3983893
Barbieri B et al. p-Aminobenzoic acid, but not its metabolite p-acetamidobenzoic acid, inhibits thrombin induced thromboxane formation in human platelets in a non NSAID like manner. 1997 Thromb. Res. pmid:9175234